Literature DB >> 19861625

Population seroprevalence of hepatitis E virus antibodies in rural Bangladesh.

Alain B Labrique1, K Zaman, Zahid Hossain, Parimalendu Saha, Mohammad Yunus, Anowar Hossain, John Ticehurst, Kenrad E Nelson.   

Abstract

Hepatitis E virus (HEV) causes a substantial burden of sporadic and epidemic disease worldwide. HEV infections result in serious morbidity and mortality, especially among pregnant women, and have significant economic costs. Few population-based studies have characterized the epidemiology of HEV. A rural Bangladeshi population was studied to determine the age- and gender- specific population seroprevalence of antibodies to HEV. Of 1,134 specimens tested from a representative, random population sample, 255 (22.5%) were anti-HEV IgG seropositive. Seroprevalence was lower among women (19.7%) than among men (25.8%). We found anti-HBc (hepatitis B core) in 380 of 1080(35.2%) tested, anti-HCV (hepatitis C) in 14 of 917(1.5%) tested, and anti-HAV (hepatitis A) in 116 of 124(93.5%) tested individuals. Our data suggest that viral hepatitis, especially HEV, remains an under-recognized and significant public health problem in rural Bangladeshi populations, warranting further attention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861625     DOI: 10.4269/ajtmh.2009.09-0352

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  27 in total

Review 1.  Epidemiology of Genotype 1 and 2 Hepatitis E Virus Infections.

Authors:  Kenrad E Nelson; Alain B Labrique; Brittany L Kmush
Journal:  Cold Spring Harb Perspect Med       Date:  2019-06-03       Impact factor: 6.915

2.  Hepatitis a and e infection in international travellers.

Authors:  Joseph Torresi; Douglas Johnson
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

3.  Surveillance at Private Laboratories Identifies Small Outbreaks of Hepatitis E in Urban Bangladesh.

Authors:  Hossain M S Sazzad; Alain B Labrique; Chong-Gee Teo; Stephen P Luby; Emily S Gurley
Journal:  Am J Trop Med Hyg       Date:  2016-12-19       Impact factor: 2.345

4.  Epidemiology and risk factors of incident hepatitis E virus infections in rural Bangladesh.

Authors:  Alain B Labrique; K Zaman; Zahid Hossain; Parimalendu Saha; Mohammad Yunus; Anowar Hossain; John R Ticehurst; Kenrad E Nelson
Journal:  Am J Epidemiol       Date:  2010-08-26       Impact factor: 4.897

Review 5.  Hepatitis E virus infection: Epidemiology and treatment implications.

Authors:  Ga Young Lee; Kittiyod Poovorawan; Duangnapa Intharasongkroh; Pattaratida Sa-Nguanmoo; Sompong Vongpunsawad; Chintana Chirathaworn; Yong Poovorawan
Journal:  World J Virol       Date:  2015-11-12

Review 6.  Hepatitis E, a vaccine-preventable cause of maternal deaths.

Authors:  Alain B Labrique; Shegufta S Sikder; Lisa J Krain; Keith P West; Parul Christian; Mahbubur Rashid; Kenrad E Nelson
Journal:  Emerg Infect Dis       Date:  2012-09       Impact factor: 6.883

7.  Clinical characteristics and risk factors of sporadic Hepatitis E in central China.

Authors:  Shujun Zhang; Jingjing Wang; Quan Yuan; Shengxiang Ge; Jun Zhang; Ningshao Xia; Deying Tian
Journal:  Virol J       Date:  2011-04-01       Impact factor: 4.099

8.  A study of viral hepatitis e infection in a tertiary care hospital in mysore, South India.

Authors:  Karkala Achutha Sudharshana Murthy; Ismailkhan Mohammed Khan; Pura Krishnamurthy Kiran; Hisham Hakeem
Journal:  Open Forum Infect Dis       Date:  2014-06-19       Impact factor: 3.835

9.  Epidemiology of Hepatitis E Virus in an Urban Community in Dhaka City.

Authors:  Salimur Rahman; Munira Jahan; Shahina Tabassum; Sheikh Mohammad Fazle Akbar
Journal:  Euroasian J Hepatogastroenterol       Date:  2014-01-22

10.  An exploratory case control study of risk factors for hepatitis E in rural Bangladesh.

Authors:  Alain B Labrique; K Zaman; Zahid Hossain; Parimalendu Saha; Mohammad Yunus; Anowar Hossain; John Ticehurst; Brittany Kmush; Kenrad E Nelson
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.